TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 173 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 1.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $135,720 | +6.6% | 16,511 | 0.0% | 0.00% | – |
| Q1 2024 | $127,300 | -14.2% | 16,511 | 0.0% | 0.00% | -100.0% |
| Q4 2023 | $148,434 | +0.6% | 16,511 | 0.0% | 0.00% | 0.0% |
| Q3 2023 | $147,608 | -23.1% | 16,511 | +32.0% | 0.00% | 0.0% |
| Q2 2023 | $192,061 | -30.6% | 12,504 | +1.6% | 0.00% | 0.0% |
| Q1 2023 | $276,874 | +39.6% | 12,311 | +30.5% | 0.00% | 0.0% |
| Q4 2022 | $198,355 | +7.2% | 9,432 | +25.7% | 0.00% | 0.0% |
| Q3 2022 | $185,000 | +1.6% | 7,504 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $182,000 | -26.9% | 7,504 | -22.4% | 0.00% | 0.0% |
| Q1 2022 | $249,000 | -25.0% | 9,673 | -9.5% | 0.00% | -50.0% |
| Q4 2021 | $332,000 | +78.5% | 10,686 | +39.1% | 0.00% | +100.0% |
| Q3 2021 | $186,000 | +66.1% | 7,680 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $112,000 | -40.7% | 7,676 | +1.2% | 0.00% | 0.0% |
| Q1 2021 | $189,000 | -10.4% | 7,587 | -1.9% | 0.00% | 0.0% |
| Q4 2020 | $211,000 | – | 7,734 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 1,026,300 | $21,583 | 6.98% |
| Deep Track Capital, LP | 4,582,000 | $96,359,460 | 4.05% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 379,019 | $7,963,189 | 2.46% |
| ARMISTICE CAPITAL, LLC | 6,412,000 | $134,844,360 | 2.35% |
| GREAT POINT PARTNERS LLC | 475,000 | $9,989,250 | 1.96% |
| RA Capital Management | 3,984,681 | $83,797,841 | 1.70% |
| MPM BioImpact LLC | 281,711 | $5,924,382 | 1.54% |
| HighVista Strategies LLC | 121,834 | $2,562,169 | 1.52% |
| Kynam Capital Management, LP | 418,099 | $8,792,622 | 1.35% |
| SECTORAL ASSET MANAGEMENT INC | 292,320 | $6,147,490 | 1.19% |